secwatch.observer — SEC 8-K summary
======================================

Issuer:     KalVista Pharmaceuticals, Inc. (KALV)
CIK:        0001348911
Form:       8-K
Filed at:   2023-06-14T23:59:59+00:00
Accession:  0000950170-23-027974
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KalVista amends CFO employment agreement raising base salary to $565K; updates bylaws for universal proxy rules
--------------------------------------------------------------------------------

- CFO Benjamin L. Palleiko's base salary raised to $565,000 (effective May 1, 2023); target bonus increased to 50% of salary.
- Severance: 15 months base salary and COBRA if terminated without cause/for good reason before Change in Control.
- If terminated within 2 years after Change in Control: 21 months base salary, full target bonus, full equity vesting, COBRA.
- Bylaws amended for DGCL updates, universal proxy rules, and exclusive forum (Delaware Chancery Court).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348911/000095017023027974/0000950170-23-027974-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348911/000095017023027974/kalv-20230608.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-027974

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer